January 16, 2005 -- Even after a .88% recovery on Friday, the Centient Biotech 200 dropped a net 2.8% last week, losing 97 points to 3366.78. That brings the loss to 6% so far in 2005, even though the JPMorgan Healthcare Conference had a positive tone, with many companies delivering positive reports. Last week’s good news includes a very large FDA approval at American Pharma, an oncology drug advancing at Cel-Sci, a collaboration for Xenova, revenue affirmation at Celgene, a strategic buy-out for Invitrogen, and good moves for recent IPOs Immunicon, Conor, and Barrier Therapeutics...
